Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...

The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...

Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

With up to 2.4 million U.S. cases and over 250 million chronic cases globally, hepatitis B infection persists despite the availability of a vaccine. Vaccines work by immunizing the body against a ...

Assembly and budding of a virus from a membrane microdomain. Viruses have an outer protein shell called a capsid which surrounds the viral nucleic acid. Enveloped viruses, such as HIV, have an ...

Though treatments are available, there is no cure or vaccine from HIV, which impacts about 38 million people worldwide. It's difficult to target the RNA genome of the HIV virus in part because it ...

The phenomenon of adeno-associated virus (AAV) capsid-promoter interaction recently seen in the rat central nervous system has now been shown to occur in the non-human primate brain. This interaction ...

We performed the first ever simulations of simultaneous capsid assembly and encapsulation of a polymer, we characterized the role of the polymer in this cooperative assembly process and obtained ...

Abselion, a pioneering life sciences technology company focused on simplifying biomolecule quantification, has expanded its product offering, with the launch of the AAVX Total Capsid Quantification ...